University Hospital of Heraklion, Department of Ophthalmology, Crete, Greece.
Can J Ophthalmol. 2011 Apr;46(2):196-8. doi: 10.3129/i10-109.
To evaluate the safety and efficacy of contact transcleral ciliary body photodynamic treatment (CB-PDT) with verteporfin in human eyes.
Prospective interventional case series.
Five glaucomatous blind eyes of 5 patients.
Verteporfin (6 mg/m(2)) was infused in bolus and then the ciliary body was irradiated transclerally with a fibre optic device. Twelve spots were placed 360° and 0.5 mm behind the sclerocorneal limbus. Laser power was 80 mW and irradiation time was 3 minutes.
The average intraocular pressure reduction was 30% after the first month and remained below pre-treatment levels throughout a 3-month follow-up. No serious adverse events were reported.
CB-PDT for refractory glaucoma was safe and efficient in human eyes; larger studies are required to evaluate its possible clinical role.
评估应用血啉甲醚经巩膜睫状体光动力疗法（CB-PDT）治疗人类青光眼的安全性和有效性。
前瞻性干预性病例系列研究。
5 例患者的 5 只青光眼盲眼。
静脉推注血啉甲醚（6mg/m2），然后用光纤设备经巩膜对睫状体进行光动力治疗。在 360°角和角巩缘后 0.5mm 处放置 12 个光斑。激光功率为 80mW，辐照时间为 3 分钟。
治疗后第 1 个月眼压平均下降 30%，在 3 个月的随访期间眼压一直低于治疗前水平。未报告严重不良事件。
CB-PDT 治疗难治性青光眼在人类眼中是安全有效的；需要更大的研究来评估其可能的临床作用。
